Health Catalyst (NASDAQ:HCAT) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Health Catalyst (NASDAQ:HCATGet Rating) released its quarterly earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.05, MarketWatch Earnings reports. Health Catalyst had a negative net margin of 63.33% and a negative return on equity of 21.30%. The business had revenue of $68.09 million for the quarter, compared to the consensus estimate of $66.01 million. During the same period in the prior year, the company posted ($0.37) earnings per share. Health Catalyst’s revenue was up 21.9% compared to the same quarter last year. Health Catalyst updated its FY 2022 guidance to EPS and its Q2 2022 guidance to EPS.

Shares of HCAT traded up $0.52 during midday trading on Wednesday, hitting $13.47. 20,504 shares of the company traded hands, compared to its average volume of 719,215. The stock has a 50-day moving average of $22.49 and a 200-day moving average of $32.50. Health Catalyst has a one year low of $12.53 and a one year high of $59.50. The firm has a market cap of $726.53 million, a P/E ratio of -4.19 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.46 and a quick ratio of 5.46.

HCAT has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of Health Catalyst in a research note on Friday, February 11th. They issued a “buy” rating and a $48.00 price target on the stock. BTIG Research dropped their price target on shares of Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. Zacks Investment Research lowered shares of Health Catalyst from a “buy” rating to a “hold” rating in a research note on Wednesday. SVB Leerink decreased their price target on shares of Health Catalyst from $64.00 to $48.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. Finally, Raymond James cut their price target on shares of Health Catalyst from $70.00 to $40.00 and set a “strong-buy” rating on the stock in a report on Friday, March 4th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $34.85.

In other news, General Counsel Daniel H. Orenstein sold 4,112 shares of the stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $26.82, for a total transaction of $110,283.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Linda Llewelyn sold 2,039 shares of the firm’s stock in a transaction on Tuesday, March 15th. The stock was sold at an average price of $21.08, for a total value of $42,982.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,286 shares of company stock worth $934,979. Company insiders own 2.00% of the company’s stock.

Several large investors have recently modified their holdings of the company. Advisor Group Holdings Inc. increased its holdings in shares of Health Catalyst by 86.3% during the first quarter. Advisor Group Holdings Inc. now owns 5,324 shares of the company’s stock valued at $137,000 after acquiring an additional 2,467 shares in the last quarter. Norges Bank bought a new position in shares of Health Catalyst in the 4th quarter worth approximately $6,029,000. BlackRock Inc. lifted its stake in shares of Health Catalyst by 0.5% in the 4th quarter. BlackRock Inc. now owns 4,699,392 shares of the company’s stock worth $186,189,000 after purchasing an additional 23,211 shares during the period. William Blair Investment Management LLC lifted its stake in shares of Health Catalyst by 1.1% in the 4th quarter. William Blair Investment Management LLC now owns 802,270 shares of the company’s stock worth $31,786,000 after purchasing an additional 8,571 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Health Catalyst by 12.3% in the 4th quarter. California State Teachers Retirement System now owns 65,103 shares of the company’s stock worth $2,579,000 after purchasing an additional 7,115 shares during the period. Hedge funds and other institutional investors own 97.53% of the company’s stock.

Health Catalyst Company Profile (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Featured Articles

Earnings History for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.